mitoxantrone has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burkhart, RA | 1 |
| Peng, Y | 1 |
| Norris, ZA | 1 |
| Tholey, RM | 1 |
| Talbott, VA | 1 |
| Liang, Q | 1 |
| Ai, Y | 1 |
| Miller, K | 1 |
| Lal, S | 1 |
| Cozzitorto, JA | 1 |
| Witkiewicz, AK | 1 |
| Yeo, CJ | 1 |
| Gehrmann, M | 1 |
| Napper, A | 1 |
| Winter, JM | 1 |
| Sawicki, JA | 1 |
| Zhuang, Z | 1 |
| Brody, JR | 1 |
1 other study available for mitoxantrone and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor | 2013 |